Ashland Inc. (ASH) Q3 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026, and the nine months ended June 30, 2026. Ashland Inc. is a global additives and specialty ingredients company operating through four reportable segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. The company is a large accelerated filer with 45.8 million shares of common stock outstanding as of the period end.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2026 | Nine Months Ended June 30, 2026 |
|---|---|---|
| Sales | $497 | $1,365 |
| Gross Profit | $170 | $422 |
| Operating Income | $43 | $76 |
| Net Income (Loss) | $16 | $20 |
| Diluted EPS (Net Income) | $0.35 | $0.43 |
| Adjusted EBITDA | $109 | $265 |
| Cash and Cash Equivalents | $440 | $440 (Balance Sheet) |
| Long-Term Debt | $1,374 | $1,374 (Balance Sheet) |
| Operating Cash Flow (9mo) | N/A | $295 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 7.3% year-over-year for the quarter ($497M vs. $463M) and 1.3% for the nine-month period ($1,365M vs. $1,347M). Growth was driven by higher volumes and favorable foreign currency exchange, partially offset by unfavorable price/mix and the impact of the Avoca business divestiture.
- Profitability Improvement: Operating income improved significantly to $43M from a loss of $708M in the prior year quarter. This dramatic swing is primarily due to the absence of a $706 million non-cash goodwill impairment charge recorded in the prior year (affecting Life Sciences and Specialty Additives segments).
- Cost Management: Cost of sales decreased $4M for the quarter and $14M for the nine months, driven by lower operating costs, favorable price/mix, and the divestiture of the Avoca business. Gross margin expanded to 34.2% for the quarter from 28.5% in the prior year.
- Divestitures: The company recorded a net gain of $1M on divestitures for the quarter, primarily from the sale of excess corporate real estate. In the prior year, this line item included a $183M impairment charge related to the Avoca business.
Guidance, Outlook, and Risks
- Guidance Update: Ashland reaffirmed full-year fiscal 2026 sales guidance of $1,835 to $1,870 million and Adjusted EBITDA guidance of $385 to $400 million. However, the company revised its Adjusted Diluted EPS outlook to "low-to-mid-single digit growth" (previously mid-to-high-single digit) due to a higher tax rate associated with unfavorable discrete items.
- Outlook: Management expects continued growth in Life Sciences and Personal Care end markets. Specialty Additives trends are improving. Pricing actions are expected to offset elevated raw material and freight costs in the fourth quarter.
- Liquidity: Available liquidity totaled $936 million as of June 30, 2026, comprising $440 million in cash and $496 million in unused borrowing capacity under a new $500 million revolving credit facility entered into in May 2026.
- Risks and Contingencies:
- Asbestos Litigation: The company maintains reserves of $262 million for Ashland-related claims and $183 million for Hercules-related claims. Reserves were increased by $31M and $17M respectively during the period.
- Environmental Remediation: Total reserves stand at $231 million, with a reasonably possible range of future costs up to $480 million.
- Geopolitical/Tariffs: Ongoing uncertainty regarding U.S. trade policies, tariffs, and geopolitical conflicts (e.g., Ukraine/Russia, Israel/Iran) poses risks to supply chains and demand.
- Credit Ratings: Standard & Poor's and Moody's downgraded Ashland's credit rating to BB and Ba2, respectively, during the nine months ended June 30, 2026, though the outlook remains stable.
Investor Verification Checklist
- Goodwill Impairment Impact: Verify the sustainability of operating income growth by excluding the one-time $706M impairment charge from the prior year comparison.
- Asbestos Reserve Adequacy: Review the actuarial assumptions used to increase asbestos reserves by $48M total ($31M Ashland + $17M Hercules) and the solvency of insurance carriers covering these claims.
- Adjusted EBITDA Reconciliation: Scrutinize the non-GAAP adjustments, specifically the $8M tax credit benefit and $15M in restructuring costs, to understand core operational performance.
- Credit Covenant Compliance: Confirm the company's leverage ratio (2.3x) and interest coverage ratio (6.9x) remain well within the 4.0x and 3.0x limits of the new 2026 Credit Agreement.
- Dividend Sustainability: Assess the ability to maintain the quarterly dividend of $0.42 per share given the revised EPS outlook and ongoing litigation cash outflows.